TIZONA
Live / Registered — Registered — Sections 8 & 15 accepted and acknowledged (as of 06 Aug 2025)
What this means for you
Registered since 02 Apr 2019. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 86984351
- Registration number
- 5715897
- Mark type
- Stylized text
- Filed
- 10 Jun 2015
- Published for opposition
- 03 Nov 2015
- Registered
- 02 Apr 2019
- Attorney of record
- Gene K. Park
Goods and services
- Class 042 — Scientific and technological services: research and development of pharmaceuticals and compounds for the treatment of cancer and autoimmune diseases; research and development of pharmaceuticals and compounds for modulation of the immune system and the tumor microenvironment
Owner
- TIZONA THERAPEUTICS, INC., South San Francisco, CA, US
- TIZONA THERAPEUTICS, INC., CAMBRIDGE, MA, US
- Vesuvius Pharmaceuticals, Inc., Cambridge, MA, US
- Vesuvius Pharmaceuticals, Inc., Cambridge, MA, US
Prosecution history
- 06 Aug 2025 — NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
- 06 Aug 2025 — REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
- 06 Aug 2025 — CASE ASSIGNED TO POST REGISTRATION PARALEGAL
- 02 Apr 2025 — TEAS SECTION 8 & 15 RECEIVED
- 02 Apr 2024 — COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
- 02 Apr 2019 — REGISTERED-PRINCIPAL REGISTER
- 28 Feb 2019 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 27 Feb 2019 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 30 Jan 2019 — STATEMENT OF USE PROCESSING COMPLETE
- 26 Dec 2018 — USE AMENDMENT FILED
- 30 Jan 2019 — DIVISIONAL PROCESSING COMPLETE
- 26 Dec 2018 — DIVISIONAL REQUEST RECEIVED
- 14 Jan 2019 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 08 Jan 2019 — ITU OFFICE ACTION ISSUED FOR DIVISIONAL REQUEST
- 26 Dec 2018 — TEAS REQUEST TO DIVIDE RECEIVED